APA (7th ed.) Citation

Schwentner, L. P., & Wischnik, A. (2016). Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer: Results from the prospective multi-center randomized ADEBAR trial. The breast, 27, . https://doi.org/10.1016/j.breast.2016.03.003

Chicago Style (17th ed.) Citation

Schwentner, Lukas Paul, and Arthur Wischnik. "Short Term Quality of Life with Epirubicin-fluorouracil-cyclophosphamid (FEC) and Sequential Epirubicin/cyclophosphamid-docetaxel (EC-DOC) Chemotherapy in Patients with Primary Breast Cancer: Results from the Prospective Multi-center Randomized ADEBAR Trial." The Breast 27 (2016). https://doi.org/10.1016/j.breast.2016.03.003.

MLA (9th ed.) Citation

Schwentner, Lukas Paul, and Arthur Wischnik. "Short Term Quality of Life with Epirubicin-fluorouracil-cyclophosphamid (FEC) and Sequential Epirubicin/cyclophosphamid-docetaxel (EC-DOC) Chemotherapy in Patients with Primary Breast Cancer: Results from the Prospective Multi-center Randomized ADEBAR Trial." The Breast, vol. 27, 2016, https://doi.org/10.1016/j.breast.2016.03.003.